Publication Listing for the MeSH term vinblastine. Found 18 abstracts

Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium - A trial of the eastern cooperative oncology group. Cancer. 2004 Apr;100(8):1639-45.

Haas NB, Giantonio BJ, Litwin S, Minniti CJ, Fox S, Yeslow G, Reilly R, Nahum K, Greenberg R, Halbherr T, Hudes GR. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma - A phase II trial of the fox chase network. Cancer. 2003 Nov;98(9):1837-41.

Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M. Phase II study of dolastatin-10 in patients with hormone- refractory metastatic prostate adenocarcinoma. Clin Cancer Res. 2000 Nov;6(11):4205-8.

Bunn PA, Vokes EE, Langer CJ, Schiller JH. An update on North American randomized studies in non-small cell lung cancer. Semin Oncol. 1998 Aug;25(4):2-10.

Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer. 1998 Feb;77(4):562-6.

Ranganathan S, Dexter DW, Benetatos CA, Hudes GR. Cloning and sequencing of human beta(III)-tubulin cDNA: induction of beta(III) isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. Biochimica Et Biophysica Acta-Gene Structure and Expression. 1998 Jan 21;1395(2):237-45.

Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1997 Sep;15(9):3156-63.

Ranganathan S, Salazar H, Benetatos CA, Hudes GR. Immunohistochemical analysis of beta-tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy. Prostate. 1997 Mar;30(4):263-8.

Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR. Increase of beta(III)- and beta(IVa)-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 1996 Jun;56(11):2584-9.

Smith CD, Zhang XQ. Mechanism of action of cryptophycin - Interaction with the Vinca alkaloid domain of tubulin. J Biol Chem. 1996 Mar 15;271(11):6192-8.

Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, True L, Shipley W. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996 Jan;14(1):119-26.

Zhang XQ, Smith CD. Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance. Mol Pharmacol. 1996 Feb;49(2):288-94.

Hudes GR, Nathan FE, Khater C, Greenberg R, Gomella L, Stern C, McAleer C. Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate-Cancer. Semin Oncol. 1995 Oct;22(5):41-5.

Hudes GR, Obasaju C, Chapman A, Gallo J, McAleer C, Greenberg R. Phase-I Study of Paclitaxel and Estramustine - Preliminary Activity in Hormone-Refractory Prostate-Cancer. Semin Oncol. 1995 Jun;22(3):6-11.

Smith CD, Zilfou JT, Zhang XQ, Hudes GR, Tew KD. Modulation of P-Glycoprotein Activity by Estramustine Is Limited by Binding to Plasma-Proteins. Cancer. 1995 May 15;75(10):2597-604.

Smith CD, Mooberry SL, Zhang XQ, Helt AM. A Sensitive Assay for Taxol and Other Microtubule-Stabilizing Agents. Cancer Lett. 1994 May 16;79(2):213-9.

Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD, Tew KD. P-Glycoprotein Binding and Modulation of the Multidrug- Resistant Phenotype by Estramustine. J Natl Cancer Inst. 1994 May 04;86(9):688-94.

Speicher LA, Laing N, Barone LR, Robbins JD, Seamon KB, Tew KD. Interaction of an Estramustine Photoaffinity Analog with Cytoskeletal Proteins in Prostate Carcinoma-Cells. Mol Pharmacol. 1994 Nov;46(5):866-72.

The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

vinblastine estramustine tubulin taxol binding microtubule assembly invitro cancer invitro cells trial bovine brain doxorubicin monoclonal-antibody multidrug-resistance chemotherapy analogs SURVIVAL agents in-vitro phase-ii microtubule dynamics cisplatin methotrexate antimicrotubule agents cooperative-oncology-group microtubules carcinoma cell-lines KeyWords Plus: proteins microtubule-associated proteins du-145 carcinoma drug resistance reverse multidrug-resistance gene CHEMOTHERAPY ifosfamide plasma proteins southwest-oncology-group progesterone 5-fluorouracil carboplatin alpha- prostate- drug p-glycoprotein iii isotype TAMOXIFEN PLUS VINBLASTINE antimicrotubule activity surgery polymerization oncology- prostate cancer tubulin isotype oral estramustine phosphate radiation-therapy beta-tubulin isotypes antimitotic drug phase-ii trial suramin group kinetic stabilization salvage cystectomy resistance colchicine REGIMEN cell-proliferation beta-tubulin assembly modulation alpha-tubulin survival 4-dichlorobenzyl thiocyanate colchicine binding urothelial carcinoma METASTATIC BLADDER-CANCER leukemia group-b and cisplatin (M-VAC) regimen expression mechanism radiotherapy mitoxantrone etoposide transitional-cell-carcinoma inhibition carboplatin and paclitaxel (CP) regimen adenylyl cyclase pharmacology dynamic instability estramustine-phosphate differentiation cancer cells ANTIMITOTIC DRUG TRANSITIONAL-CELL-CARCINOMA antigen structural features REFRACTORY PROSTATE-CANCER antineoplastic agents proliferation dolastatin-10 drugs auristatin-pe colchicine-binding-site glucose transporter cytotoxicity irradiation COMBINATION binds microtubule renal cell carcinoma phosphate isotypes 2 griseofulvin RESISTANCE multiple-drug quality of life molecular-weight resistant antimitotic agent verapamil apoptosis